Business
Suda Pharmaceuticals share price soars 200% on TGA approval – Motley Fool Australia
The Suda Pharmaceuticals share price is soaring over 200% following TGA approval for its insomnia treatment product, ZolpiMist.
The Suda Pharmaceuticals Ltd(ASX: SUD) share price has soared 207.4% today, at the time of writing. The surge came following the company’s announcement that its Zolpimist product has been approved by the TGA (Therapeutic Goods Administration). ZolpiMist is an oral spray for the treatment of insomnia.
In an investor presentation released by Suda Pharmaceuticals earlier this month, the company estimated the market for insomnia treatments will be approximately US$4 billion by 2026. Furthermore, a…
-
Noosa News23 hours agoMajor crash on Gateway Motorway snarls morning commute
-
Noosa News19 hours agoDriver arrested after life-threatening hit-and-run on outskirts of Ipswich, Queensland
-
Business21 hours agoThis ASX 200 mining stock is eyeing the lithium throne
-
Business19 hours agoThe best ASX shares to buy and forget for 10+ years